Ribomic Inc.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2025 | 2026 | |
|---|---|---|---|
| Income Statement | |||
| Revenue | ¥66M | ¥2M | ¥3M |
| Gross Profit | - | - | - |
| Operating Income | -¥1,786M | -¥1,051M | -¥1,207M |
| Pretax Income | -¥1,786M | -¥1,051M | -¥1,207M |
| Net Income | -¥1,653M | -¥1,019M | -¥1,145M |
| EPS | -¥53.14 | -¥25.21 | -¥23.07 |
| Operating Margin | -2,707.39% | -49,861.84% | -40,237.73% |
| Balance Sheet | |||
| Total Assets | ¥4,584M | ¥3,186M | ¥2,976M |
| Total Equity | ¥4,384M | ¥3,044M | ¥2,841M |
| Total Liabilities | ¥199M | ¥142M | ¥135M |
| Cash | ¥2,825M | ¥1,837M | ¥1,927M |
| Interest-bearing Debt | - | - | - |
| Equity Ratio | 95.65% | 95.54% | 95.46% |
| D/E Ratio | 0.00 | 0.00 | 0.00 |
| Cash Flow | |||
| Operating CF | -¥1,709M | -¥997M | -¥1,111M |
| Investing CF | ¥276M | ¥67M | ¥290M |
| Financing CF | ¥1,334M | ¥667M | ¥911M |
| Free CF | -¥1,733M | -¥1,030M | -¥1,121M |
| Efficiency | |||
| ROE | -37.70% | -33.48% | -40.31% |
| ROA | -36.06% | -31.98% | -38.48% |
Latest IR Information
-
Domestic Phase 3 Clinical Trial of Omedaptanib Pegol for Achondroplasia: Announcement of Expanded Investigational Sites
Expansion of domestic Phase 3 clinical trial sites for achondroplasia treatment Umepaptanib pegol to 16 sites nationwide (cumulative 10 sites currently, plan to 16); no impact on fiscal year 2027 performance. Subjects are pediatric patients with rare diseases; new IRB-approved...
Read more -
【RevoMic】Q2 FY2024 Financial Results｜Revenue Unknown (YoY Unknown)
RevoMic has secured confirmed government grants for FY2025 and is promoting the development of foundational technology for drug discovery research utilizing quantum and AI technologies. Grant income is scheduled to be recognized as non-operating income within FY2026.
Read more -
Notice of Public Disclosure of JRCT Registration Information for Domestic Phase III Clinical Trial of Growth Hormone-Deficient Osteogenesis/Osteochondral Hypoplasia Treatment (umedaptanib pegol)
Read more -
Notice of Grant Award for FY2026 Rare Disease Medicines Research Grants (umedaptanib pegol)
Read more -
Notice of First Case Registration in Domestic Phase III Clinical Trial of Treatment for Achondroplasia (umedaptanib pegol)
Read more
Latest News (5 items)
Company Information
About
Ribomic Inc. engages in the discovery and development of pharmaceutical compounds using RNA aptamers in Japan and Europe. The company develops RBM-007, which is in Phase III clinical trial for the treatment of achondroplasia; Phase II clinical trial for the treatment of wet age-related macular degeneration; and pre-clinical trial for the treatment of diabetic macular edema. It is also involved in the development of drugs in pre-clinical trial stage, including RBM-006 for the treatment of retinal disease, proliferative, vitreoretinopathy, glaucoma, and diabetic retinopathy; RBM-011 for the treatment of pulmonary arterial hypertension; RBM-003 for the treatment of heart failure; RBM-010 for the treatment of osteoarthritis; and RBM-009 for the treatment of severe asthma, as well as RBM-101, which is in discovery stage for the affinity purification of human IgG and Fc-fusion proteins. The company was incorporated in 2003 and is headquartered in Minato, Japan.
